Revolutionizing the preimplantation genetic testing laboratory allowing for greater access, accuracy, and clinical impact
At NOVA Genomics, we are reimagining preimplantation genetic testing (PGT). Founded by industry veterans Dr. Gary Harton and Cynthia Hudson, NOVA brings together cutting-edge technology and a new standard of care to help patients and IVF providers navigate the complexities of genetic testing through informed decision making.
PGT is offered as three options: PGT-A, PGT-M, and PGT-SR, each designed to address different genetic concerns.
Preimplantation Genetic Testing for Aneuploidy (PGT-A) is a genetic test to screen embryos for numerical chromosome changes (i.e. Down syndrome). This test identifies embryos predicted to have the expected complement of chromosomes.
NOVA Genomics was founded by two pioneers in the IVF industry. Cynthia Hudson and Dr. Gary Harton, who bring over 50 years of combined experience in Embryology and Preimplantation Genetic Testing (PGT). After decades of work, they recognized critical gaps in the field, including outdated lab technologies, growing concerns about quality and compliance, and ongoing debates over the clinical value of PGT.
Their response was to build a next-level PGT lab from the ground up, focused on expanding access to advanced genetic services for families in need of PGT-SR and PGT-M testing for inherited conditions.
Driven by this mission, NOVA Genomics is transforming the PGT experience through:
Expert genetic counseling, seamlessly integrated. Through our partnership with Tandem Genetics, clinics have access to experienced telehealth counselors for pre- and post-testing sessions. This service streamlines care and ensures individuals pursuing IVF with PGT receive clear guidance on results and next steps.
Learn more about Tandem Genetics’ virtual counseling services.
Chief Scientific Officer
Gary brings 35 years of experience covering embryology and andrology, molecular and classic cytogenetics, next-generation sequencing, and clinical genetics.
Cynthia is a medical technologist with over 25 years of experience as an embryologist, entrepreneur, and product specialist.
Dr. Stern is a Board-Certified Clinical & Molecular Geneticist specializing in Reproductive Genetics. He has over 30 years of experience as Medical Director of Preimplantation Genetic Testing and Molecular Genetics laboratories.
Director of Clinical Services
Director Laboratory Services
Lab Team Lead SNV
Khoa has 20 years of research and clinical experience applying molecular diagnostics to the field of reproductive genetics.
BS Lab Intern
Gabrielle is a current biotechnology graduate student with a background in Biology and a growing foundation in Computational Genomics and Molecular Science.
Professor Darren Griffin is a distinguished geneticist and reproductive medicine expert who serves as Honorary Professor at University College London and the University of Kent, and CEO of GriffinLore Ltd. With over 400 peer-reviewed publications and a citation count exceeding 24,000, he is internationally recognized for his groundbreaking work in preimplantation genetic testing, having co-developed Karyomapping—a universal diagnostic test used to treat over 50,000 patients worldwide. His research spans human fertility and embryology, comparative genomics, and chromosome evolution, with particular expertise in applying genomic technologies to improve reproductive outcomes and agricultural breeding programs. Professor Griffin brings extensive experience in translating cutting-edge genetic research into clinical applications and commercial solutions, making him an invaluable advisor for genomics companies focused on reproductive health and diagnostics.
Emily Wiseman is a molecular biologist with deep expertise in assay development, single-cell genomics, and method innovation. She has led cross-functional teams in advancing next-generation sequencing technologies, contributed to a pending patent in novel genomics workflows, and delivered validated solutions across ddPCR, qPCR, and RNA single-cell sequencing platforms. Emily earned her Ph.D. in Cell and Molecular Biology from the Florida Institute of Technology, where her research pioneered transcriptomic and proteomic analyses of fertilization processes. At Nova Genomics, she brings a proven track record of scientific excellence, technical leadership, and innovation to accelerate reproductive genetics and clinical applications.
NOVA Genomics’ founders benefit from over 50 years of combined experience in embryology and reproductive genetics, ensuring a profound understanding of the field.
Unlike many competitors that have evolved from existing frameworks, NOVA Genomics was designed from the ground up to address specific gaps in PGT, focusing on modern technology, quality, and compliance.
By leveraging the latest advancements in genetic testing, NOVA Genomics ensures high accuracy and reliability in its results, setting a new standard in the industry.
Understanding the nuances of IVF treatments, NOVA Genomics works closely with clinics to provide seamless integration of its testing services, enhancing overall patient care.
